Several media have reported on the collaboration of Nostrum Biodiscovery, a company cofounded by IRB Barcelona researcher Modesto Orozco, with Grifols and IrsiCaixa. This spin-off company from IRB Barcelona will contribute to research into COVID-19 by providing data that will facilitate the intelligent design of drugs in silico for the treatment of coronavirus.
The company has issued a press release to announce this collaboration and the appointment of its new CEO, Ezequiel Mas del Molino. Nostrum Biodiscovery thus begins a new period marked by an ambitious growth plan in which it will strengthen its present in the European and US markets.
Link to: Expansión
Link to: Europa Press
Link to: Siglo XXI
Link to: La Vanguardia
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).